4
Changes in Ownership
TEVA PHARMACEUTICAL INDUSTRIES LTD Filed Acc 0000950170-25-034607
Exec. VP, European Commercial sold 140,372 shares at an average $15.80 ($2,217,407)
- Exec. VP, European Commercial acquired 237,142 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Daniell Richard · Exec. VP, European Commercial
Table I: Non-derivative
9 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2025-03-04 | Exercise or conversion : show line 1 in the form 10b5-1 | +33,512 | 33,512 | D | ||
| 2025-03-04 | Sale : show line 2 in the form 10b5-1 | −21,870 | $15.73 | $344,116 | 11,641 | D |
| 2025-03-05 | Sale : show line 3 in the form 10b5-1 | −11,641 | $15.91 | $185,246 | 0 | D |
| 2025-03-04 | Exercise or conversion : show line 4 in the form 10b5-1 | +20,461 | 20,461 | D | ||
| 2025-03-04 | Sale : show line 5 in the form 10b5-1 | −13,353 | $15.73 | $210,104 | 7,108 | D |
| 2025-03-05 | Sale : show line 6 in the form 10b5-1 | −7,108 | $15.91 | $113,111 | 0 | D |
| 2025-03-04 | Exercise or conversion : show line 7 in the form 10b5-1 | +183,169 | 183,169 | D | ||
| 2025-03-04 | Sale : show line 8 in the form 10b5-1 | −56,385 | $15.73 | $887,195 | 126,784 | D |
| 2025-03-05 | Sale : show line 9 in the form 10b5-1 | −30,015 | $15.91 | $477,635 | 96,769 | D |
| Open-market sales · 140,372 sh · avg $15.80 · $2,217,407 | ||||||
Table II: Derivative
3 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2025-03-04 | Exercise or conversion : show line 10 in the form 10b5-1 Restricted Share Units | −33,512 | 33,512 | D |
| 2025-03-04 | Exercise or conversion : show line 11 in the form 10b5-1 Restricted Share Units | −20,461 | 61,384 | D |
| 2025-03-04 | Exercise or conversion : show line 12 in the form 10b5-1 Restricted Share Units | −183,169 | 0 | D |
Loading xslF345X05/ownership.xml…